Sodium-glucose transporter inhibition in heart failure: from an unexpected side effect to a novel treatment possibility

This publication has 94 references indexed in Scilit:

• Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
  The Journal of Clinical Endocrinology & Metabolism, 2012
• SGLT2 Deletion Improves Glucose Homeostasis and Preserves Pancreatic β-Cell Function
  Diabetes, 2011
• Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms
  New England Journal of Medicine, 2011
• Elevated Cytosolic Na ⁺ Increases Mitochondrial Formation of Reactive Oxygen Species in Failing Cardiac Myocytes
  Circulation, 2010
• Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats
  Life Sciences, 2005
• Phlorizin: a review
  Diabetes/Metabolism Research and Reviews, 2004
• Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
  British Journal of Nutrition, 2003
• Effects of Enalapril on Mortality in Severe Congestive Heart Failure
  New England Journal of Medicine, 1987
• Phlorizin as a competitive inhibitor of the active transport of sugars by hamster small intestine, in vitro
  Biochimica et Biophysica Acta, 1962
• THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN
  Journal of Clinical Investigation, 1933